Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the treatment of glioblastoma. Vortioxetine, an antidepressant, showed promising anti-glioblastoma activity, significantly reducing tumor size in preclinical trials.
Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer
SAN FRANCISCO — Adding the novel anti-TIGIT monoclonal antibody tiragolumab plus atezolizumab (Tecentriq) to standard first-line chemotherapy significantly improved survival for patients with advanced esophageal